guselkumab vs QL2106
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT02203032 · Phase 3 · completed
In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.
Next expected readout: December 2026 · NCT05004727 (registry estimate)
Reported efficacy
Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)
Result source: NCT02203032
QL2106
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07511647 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | QL2106 |
|---|---|---|
| PASI 75 | 84.1% vs 6.3%+77.8 vs placeboNCT0232521911 other results
| —Trial running · NCT07511647 |
| PASI 90 | 70% vs 2.4%+67.6 vs placeboNCT0220724410 other results
| —Trial running · NCT07511647 |
| PASI 100 | 50% vs 0%+50 vs placeboNCT029053313 other results
| —Trial running · NCT07511647 |
| sPGA 0/1 | 85.7% vs 7.1%+78.6 vs placeboNCT014835994 other results
| —Trial running · NCT07511647 |
| DLQI, change | -11.2 vs -2.6−8.6 vs placeboNCT0220724410 other results
| —Trial running · NCT07511647 |
PASI 75
- guselkumab
- 84.1% vs 6.3%+77.8 vs placeboNCT02325219
11 other results
- 89.2% vs 6.3% NCT02325219
- 86.3% vs 68.5% NCT02207244
- 92.7% vs 92.8% NCT03090100
- 89.3% vs 91.6% NCT03090100
- 91.2% vs 73.1% NCT02207231
- 78.6% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 81% vs 4.8% NCT01483599
- 75.6% vs 4.8% NCT01483599
- 43.9% vs 4.8% NCT01483599
- 5.1% vs 22.9% NCT03573323
- QL2106
- —Trial running · NCT07511647
PASI 90
- guselkumab
- 70% vs 2.4%+67.6 vs placeboNCT02207244
10 other results
- 73.3% vs 2.9% NCT02207231
- 69.8% vs 0% NCT02325219
- 70.8% vs 0% NCT02325219
- 75.8% vs 0% NCT02905331
- 70% vs 46.8% NCT02207244
- 78.5% vs 79.6% NCT03090100
- 69.1% vs 76.1% NCT03090100
- 73.3% vs 49.7% NCT02207231
- 35.9% vs 58.5% NCT03573323
- 7.9% vs 21% NCT03573323
- QL2106
- —Trial running · NCT07511647
PASI 100
- guselkumab
- 50% vs 0%+50 vs placeboNCT02905331
3 other results
- 24.9% vs 41.3% NCT03573323
- 13.6% vs 29.6% NCT03573323
- 1.4% vs 6.7% NCT03573323
- QL2106
- —Trial running · NCT07511647
sPGA 0/1
- guselkumab
- 85.7% vs 7.1%+78.6 vs placeboNCT01483599
4 other results
- 78.6% vs 7.1% NCT01483599
- 83.3% vs 7.1% NCT01483599
- 61% vs 7.1% NCT01483599
- 34.1% vs 7.1% NCT01483599
- QL2106
- —Trial running · NCT07511647
DLQI, change
- guselkumab
- -11.2 vs -2.6−8.6 vs placeboNCT02207244
10 other results
- -11.2 vs -0.6 NCT02207231
- -8.5 vs -0.8 NCT02325219
- -7 vs -0.4 NCT02325219
- -8.3 vs -0.8 NCT02325219
- -7.5 vs -0.4 NCT02325219
- -10.8 vs -2.3 NCT01483599
- -11.1 vs -2.3 NCT01483599
- -11.4 vs -2.3 NCT01483599
- -10.3 vs -2.3 NCT01483599
- -6.2 vs -2.3 NCT01483599
- QL2106
- —Trial running · NCT07511647
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QL2106: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 4 of 4 rows · QL2106: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab |
|---|---|
| Dropout rate | —100 mga NCT02203032 · Phase 3 show 42 more results3.6%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 1.6%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 9.5% NCT03573323 · Phase 4 · registry result, not featured evidence 13%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 7.6%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 3.1%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 4.8%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mga NCT02203032 · Phase 3 show 42 more results1.8%100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207244 · Phase 3 —100 mg NCT02207231 · Phase 3 —100 mg NCT02207231 · Phase 3 0%Guselkumab NCT02905331 · Phase 3 —Guselkumab (Week 0-16) NCT02905331 · Phase 3 —Guselkumab (Week 16-40) NCT02905331 · Phase 3 1.6% NCT03573323 · Phase 4 · registry result, not featured evidence 1.3%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 0%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 1.9%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 0%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence —50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence —Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence —Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence —Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence —100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence —50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 2.4%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence —200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 9.5%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence —15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence —5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.7%100 mga NCT02203032 · Phase 3 show 42 more results1.6%100 mg NCT02207244 · Phase 3 2.1%100 mg NCT02207244 · Phase 3 14%100 mg NCT02207244 · Phase 3 2.5%100 mg NCT02207231 · Phase 3 2.4%100 mg NCT02207231 · Phase 3 —Guselkumab NCT02905331 · Phase 3 3.2%Guselkumab (Week 0-16) NCT02905331 · Phase 3 1.6%Guselkumab (Week 16-40) NCT02905331 · Phase 3 3.2% NCT03573323 · Phase 4 · registry result, not featured evidence 3.9%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT05272150 · Phase 3 · registry result, not featured evidence 5.3%100 mg NCT06039189 · Phase 3 · registry result, not featured evidence 4.7%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 6.3%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 2.2%100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 3.5%100 mg NCT03818035 · Phase 3 · registry result, not featured evidence 4.3%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q8W NCT03818035 · Phase 3 · registry result, not featured evidence 0%100mg NCT03818035 · Phase 3 · registry result, not featured evidence —100mg NCT03818035 · Phase 3 · registry result, not featured evidence 4%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 6.6%100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence —100 mg Q16W NCT03818035 · Phase 3 · registry result, not featured evidence 9.7%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.6%100 mg NCT02325219 · Phase 3 · registry result, not featured evidence 9.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 1.5%50 mg NCT02325219 · Phase 3 · registry result, not featured evidence 5%Part I/IIa (Week 0 to Week 32): Gu NCT02951533 · Phase 3 · registry result, not featured evidence 0%Part III (Week 64 Through Week 100 NCT02951533 · Phase 3 · registry result, not featured evidence 5.5%Part IIb (Week 32 Through Week 56) NCT02951533 · Phase 3 · registry result, not featured evidence 6.2%100 mg NCT03090100 · Phase 3 · registry result, not featured evidence 5%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%200 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01483599 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01483599 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 37 more results100 mg nasopharyngitis 7.1% (placebo 6.5%) headache 5.1% (placebo 2.8%) upper respiratory tract infection 3.2% (placebo 4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 3.7% (placebo 6.5%) upper respiratory tract infection 2.5% (placebo 4%) arthralgia 1.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 30% (placebo 6.5%) upper respiratory tract infection 23.5% (placebo 4%) arthralgia 9.7% (placebo 2.4%) NCT02207244 · Phase 3 100 mg nasopharyngitis 20.1% (placebo 9.8%) upper respiratory tract infection 9.6% (placebo 5.2%) gastroenteritis 3.4% (placebo 1.1%) NCT02207231 · Phase 3 100 mg nasopharyngitis 9.1% (placebo 9.8%) upper respiratory tract infection 7.6% (placebo 5.2%) headache 4.3% (placebo 4%) NCT02207231 · Phase 3 injection site pain 40.3% (placebo 43.8%) injection site coldness 22.6% (placebo 18.8%) injection site pruritus 12.9% (placebo 12.5%) NCT02905331 · Phase 3 injection site pain 18% (placebo 43.8%) injection site coldness 11.5% (placebo 18.8%) viral upper respiratory tract infection 9.8% (placebo 0%) NCT02905331 · Phase 3 upper respiratory tract infection 8.1% nasopharyngitis 5.3% injection site reaction 1.2% NCT03573323 · Phase 4 · registry result, not featured evidence 100 mg upper respiratory tract infection 16.9% (placebo 3.8%) nasopharyngitis 11.7% (placebo 3.8%) covid-19 6.5% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 24.7% (placebo 3.8%) covid-19 16% (placebo 0%) arthralgia 7.4% (placebo 0%) NCT05272150 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 15.1% (placebo 2.7%) nasopharyngitis 6.7% (placebo 7.1%) covid-19 4.4% (placebo 0.9%) NCT06039189 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 17.6% headache 5.4% back pain 4.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W nasopharyngitis 18.5% hypertension 5.9% arthralgia 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q8W covid-19 14.7% nasopharyngitis 12.5% psoriasis 7.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 14.1% covid-19 9.3% headache 5.7% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nasopharyngitis 24.3% headache 9% hypertension 5.5% NCT03818035 · Phase 3 · registry result, not featured evidence 100mg nail psoriasis 22.2% back pain 11.1% covid-19 11.1% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 15.4% headache 6% back pain 5.4% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg Q16W nasopharyngitis 12.4% covid-19 8.8% psoriasis 8.8% NCT03818035 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 50% (placebo 10.9%) eczema 11.3% (placebo 1.6%) injection site erythema 11.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 12.7% (placebo 10.9%) dental caries 3.2% (placebo 1.6%) upper respiratory tract infection 3.2% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 60.3% (placebo 10.9%) arthralgia 14.3% (placebo 0%) influenza 14.3% (placebo 1.6%) NCT02325219 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 21.5% (placebo 10.9%) alopecia 3.1% (placebo 0%) arthralgia 3.1% (placebo 0%) NCT02325219 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.7% headache 15% diarrhoea 11.7% NCT02951533 · Phase 3 · registry result, not featured evidence aspartate aminotransferase increased 2.8% tooth infection 2.8% abdominal discomfort 0% NCT02951533 · Phase 3 · registry result, not featured evidence nasopharyngitis 50.9% bronchitis 9.1% alanine aminotransferase increased 5.5% NCT02951533 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 22.1% upper respiratory tract infection 15.5% headache 9% NCT03090100 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 10% (placebo 2.4%) upper respiratory tract infection 7.5% (placebo 2.4%) back pain 5% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 100 mg back pain 4.8% (placebo 0%) headache 4.8% (placebo 2.4%) sinusitis 4.8% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg nasopharyngitis 17.9% (placebo 2.4%) back pain 2.6% (placebo 0%) headache 2.6% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 50 mg hypertension 7.1% (placebo 2.4%) fatigue 4.8% (placebo 7.1%) arthralgia 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 13.2% (placebo 2.4%) cough 5.3% (placebo 2.4%) upper respiratory tract infection 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 200 mg upper respiratory tract infection 7.3% (placebo 2.4%) cough 4.9% (placebo 2.4%) nasopharyngitis 4.9% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg back pain 2.4% (placebo 0%) nasopharyngitis 2.4% (placebo 2.4%) sinusitis 2.4% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 15 mg headache 9.8% (placebo 2.4%) nasopharyngitis 9.8% (placebo 2.4%) back pain 2.4% (placebo 0%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 15.8% (placebo 2.4%) upper respiratory tract infection 10.5% (placebo 2.4%) arthralgia 5.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 14.6% (placebo 2.4%) back pain 7.3% (placebo 0%) headache 7.3% (placebo 2.4%) NCT01483599 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 13 more results
show 17 more results
show 5 more results
show 5 more results
show 11 more results
show 14 more results
show 1 more result
show 1 more result
show 1 more result
+ 99 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · QL2106's landscape